Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 386,035 shares, a decrease of 23.1% from the January 29th total of 502,013 shares. Based on an average daily volume of 357,684 shares, the days-to-cover ratio is presently 1.1 days. Currently, 11.2% of the shares of the stock are sold short. Currently, 11.2% of the shares of the stock are sold short. Based on an average daily volume of 357,684 shares, the days-to-cover ratio is presently 1.1 days.

Jaguar Animal Health Stock Performance

Jaguar Animal Health stock opened at $0.97 on Monday. Jaguar Animal Health has a twelve month low of $0.56 and a twelve month high of $15.75. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08. The company’s 50-day moving average price is $0.83 and its 200-day moving average price is $1.44. The company has a market cap of $3.62 million, a PE ratio of -0.03 and a beta of 0.09.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JAGX. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.